Meredith Prithviraj Counsel

New Jersey
T 973.597.2396 | F 973.597.2397

Clients rely on Meredith for her experience in representing public companies, primarily in the pharmaceutical, life science, and health care industries. She frequently represents issuers in public and private securities offerings–including IPOs, follow-on public offerings, shelf registrations, and private placements–and regularly advises public companies and their boards on securities law compliance matters, disclosure issues, and corporate governance matters.

Prior to joining the firm, Meredith served as counsel and corporate secretary at Intelligroup, a publicly held information technology company, where she handled ’34 Act reporting, Section 404 of the Sarbanes-Oxley Act of 2002, equity compensation issues, employment law issues, corporate governance matters, and PIPE transactions. At Intelligroup, Meredith also managed outside counsel in connection with litigation matters concerning breach of fiduciary duties, post-employment restrictive covenants, and shareholder class actions.

Press Mentions

Lowenstein Sandler represented Matinas BioPharma Holdings, Inc. (MTNB-OTCQB) in connection with a $10 million private placement, which closed on April 10, 2015. Matinas sold to accredited investors an aggregate of 20,000,000 units at a price of $0.50 per unit, with each unit consisting of one share of the Company's common stock and a five-year warrant to purchase one share of common stock at an exercise price of $0.75 per share. SternAegis Ventures, through Aegis Capital Corp., acted as the exclusive Placement Agent for the offering. The Lowenstein deal team was led by Steven M. Skolnick, Michael J. Lerner, Meredith PrithvirajIrina Ishak and Robert Bee, Jr. , April 10, 2015
Lowenstein Sandler represented Celldex Therapeutics, Inc. in connection with its $200.1 million public offering of common stock underwritten by Jefferies LLC and Leerink Partners LLC as joint book-running managers, Guggenheim Securities, LLC acting as lead manager, and Oppenheimer, Brean Capital, Cantor Fitzgerald and ROTH Capital Partners as co-managers. Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Celldex’s pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. The Lowenstein team included Anthony O. Pergola, Alan Wovsaniker, Michael J. Lerner, Meredith Prithviraj, Robert J. Paradiso, Michael Amalfe and Eugene Cheval. , March 3, 2015
Lowenstein Sandler represented Roka Bioscience, Inc. in its initial public offering. Roka sold 5,000,000 shares of common stock at $12 per share, raising $60 million. The underwriters in the offering were Bank of America, Merrill Lynch, Leerink Partners, Cowen and Company and Wedbush PacGrow Life Sciences. Roka is a molecular diagnostics company that provides advanced testing solutions for the detection of foodborne pathogens in the United States. The Lowenstein deal team was led by Steven M. Skolnick, Steven B. Fuerst, Steven R. Buckingham, Meredith Prithviraj, Cindy G. Hanna, Katie Rigler and included Robert J. Paradiso, Christine Osvald-Mruz, Joseph A. Becht Jr., Tara P. D’Orsi, and Darren Goodman. , July 23, 2014
View More...

Related Areas

Capital Markets & Securities
Life Sciences
The Tech Group
Transactions & Advisory Group


Fordham University School of Law ( J.D. , 2003 )
Loyola College ( B.A. ) , History, Spanish minor, cum laude

Bar Admissions

New York
New Jersey


  • Board of Trustees of Court Appointed Special Advocates (CASA) for Children of Essex County, Board Member and Corporate Secretary